• In May 2026, IDEXX Laboratories announced that SDMA, a kidney function biomarker, had been integrated into its widely used Catalyst CLIPs, making earlier and more comprehensive renal assessment part of routine in-clinic chemistry testing across the United States and Canada.
• This move effectively embeds an IRIS-recognized biomarker into everyday veterinary workflows, broadening access to advanced kidney screening while reinforcing IDEXX’s position in companion animal diagnostics.
• We’ll now examine how embedding SDMA into routine Catalyst profiles may influence IDEXX’s recurring diagnostics revenue outlook and broader investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

IDEXX Laboratories Investment Narrative Recap

To own IDEXX, you need to believe in the steady growth of recurring companion-animal diagnostics and the stickiness of its installed base, even as U.S. clinic visit trends stay soft and competition in point of care testing remains intense. The SDMA integration strengthens the “test more per visit” theme, but does not obviously change the near term dependence on clinical visit volumes or the risk that slower instrument placements could cool consumables growth.

The SDMA news also sits alongside IDEXX’s push into cancer diagnostics, including the IDEXX Cancer Dx Panel expansion announced earlier in 2026. Together, these moves highlight a broader effort to deepen test menus around chronic and life threatening conditions, potentially increasing utilization per visit and reinforcing recurring revenue, even if international adoption and pricing power remain key swing factors for the story.

Yet, while this supports a strong product story, investors should still be aware that sustained weakness in U.S. visit growth could...

IDEXX Laboratories' narrative projects $5.2 billion revenue and $1.3 billion earnings by 2028. This requires 8.8% yearly revenue growth and roughly a $300 million earnings increase from $985.7 million today.

Uncover how IDEXX Laboratories' forecasts yield a $750.23 fair value, a 34% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were already modeling revenue of about US$5.9 billion and earnings of US$1.6 billion by 2029, view ecosystem growth and AI enabled preventive care as far more powerful catalysts than the baseline narrative suggests, so this SDMA move could either reinforce their case or prompt you to question whether such bullish outcomes are realistic.

Explore 3 other fair value estimates on IDEXX Laboratories - why the stock might be worth just $553.22!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your IDEXX Laboratories research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free IDEXX Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEXX Laboratories' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.